Skip to main content
PMC home page
F1000Research logoLink to F1000Research
. 2019 Jun 27;7:1624. Originally published 2018 Oct 10. [Version 2] doi: 10.12688/f1000research.16454.2

Large-scale analysis of B-cell epitopes of envelope: Implications for Zika vaccine and immunotherapeutic development

Iman Almansour 1,a, Rahaf Alfares 1, Halah Aljofi 1
PMCID: PMC6611143  PMID: 31316749

Version Changes

Revised. Amendments from Version 1

The questions raised by the reviewer have been adequately addressed. Methods supplemented with additional information were added.   Abstract: Correction of Antibody name ZIKV-119 to ZIKAV-19.   Introduction: The release of PrM and E proteins of Zika was further elaborated.   Methods: Additional details of protein stability prediction parameters were added. Likewise, further details of N-Glycosylation prediction were also provided.   Results: Elaboration on factors affecting protein stability was added.

Abstract

Background: Cases of the re-emergence of Zika virus in 2015 were associated with severe neurologic complications, including Gillien-Barre syndrome in adults and congenital Zika syndrome in newborns. The major structural determinant of immunity to the Zika virus is the E protein. Although B-cell epitopes of Zika E protein were recently identified, data regarding epitope variations among Zika strains in pre-epidemic and epidemic periods are lacking.

Methods: Here, we conducted systematic bioinformatics analyses of Zika strains isolated between 1968 and 2017. Multiple sequence alignment of E protein as well as B-cell epitopes annotations were performed. In addition, homology-based approach was utilized to construct three-dimensional structures of monomeric E glycoproteins to annotate epitope variations. Lastly, prediction of of N-glycosylation patterns and prediction of protein stability upon mutations were also investigated.

Results: Our analyses indicates that epitopes recognized by human mAbs ZIKV-117, ZIKV-15, and ZIKV-19 were highly conserved, suggesting as attractive targets for the development of vaccines and immunotherapeutics directed against diverse Zika strains. In addition, the epitope recognized by ZIKV-E-2A10G6 mAb derived from immunized mice was mostly conserved across Zika strains.

Conclusions: Our data provide new insights regarding antigenic similarities between Zika strains circulating worldwide. These data are essential for understanding the impact of evolution on antigenic cross-reactivity between Zika lineages and strains. Further in-vitro analyses are needed to determine how mutationsat predefined epitopes could impact the development of vaccines that can effectively neutralize Zika viruses.

Keywords: Antibody, Bioinformatics, Envelope, Epitope, Homology Modeling, Neutralizing Antibodies, Vaccine, Zika

Introduction

Zika is a positive-sense, enveloped, RNA virus of the Flaviviridae family 1, which also includes dengue virus, West Nile virus (WNV), Japanese encephalitis virus (JEV), tick-borne encephalitis virus (TBEV), and yellow fever virus (YFV) 2. Zika was originally discovered in a rhesus monkey in 1947 in Uganda 3, and the first case of spread to humans was reported in 1952 4. Since that time, the virus has spread globally, with Zika outbreaks reported in Micronesia in 2007 and in the Pacific islands in 2013–2014 5, 6. A recent outbreak that began in Brazil in 2015 that eventually spread to countries in North America and the Caribbean 7, 8.

The Zika virus genome encodes three structural proteins (capsid [C], premembrane [PrM], and envelope [E]) and seven non-structural proteins (NS1, NS2A, NS2B, NS3, NS4A, NS4B, and NS5) 2. Similar to other flaviviruses, the structural proteins and viral genome form virions that assembles as immature particles at the endoplasmic reticulum of infected cells 9. The immature particles are composed of 60 PrM/E protein heterodimers that protrude from the viral surface 10. In the Golgi apparatus, PrM is cleaved by furin-like protease to produce mature M protein and Pr protein product 2. After maturation, PrM and E are released and 90 E protein homodimers rearrange in a herringbone-like array forming mature Zika virus 11, 12.

The E protein is the major surface glycoprotein of flaviviruses and plays an essential role in virus attachment and fusion. Each E protein monomer consists of three domains: DI, DII, and DIII 13, which undergo major rearrangements during the virus maturation cycle 14, 15. DI is a central beta-barrel domain; DII is a finger-like dimerization domain; and DIII is an immunoglobulin-like domain 10, 11. DI, which connects DII to DIII, is essential for the conformational changes required for viral entry into cells 16. DII contains a fusion loop (FL) that interacts with the endosomal membrane, whereas DIII contains the receptor-binding site and is thus essential for attachment of virus particles to the host cell 15, 16. DIII also plays an essential role in mediating the fusion of virus particles with the endosomal membrane after endocytosis 17.

The global spread of Zika virus in conjunction with the neurologic consequences of infection have increased the urgency of efforts to develop Zika vaccines and immunotherapeutics. Humoral immunity is the major source of host protection against flaviviruses, in which neutralizing antibodies play an important role in virus clearance 18. Antibodies generated against the E protein have been shown to block the entry of viruses into host cells 19. Previous attempts to map the antigenic epitopes of the Zika E protein utilized antibodies specific for other flaviviruses, such as dengue virus 20– 22. Recently, several B-cell antigenic epitopes within an individual E domain were identified in studies of antibodies isolated from Zika-virus infected patients 23– 25 and Zika-vaccinated mice 13, 26, 27.

Although antigenic epitopes of the E protein have been characterized based on maps prepared using Zika-specific antibodies, no systematic analyses of the specificity of Zika monoclonal antibodies (mAbs) for available Zika E protein sequences have been conducted. Such data are particularly important, as RNA viruses exhibit high mutation rates and can generate mutations that enable them to evade the host immune system. Importantly, the structural stability of E protein is a key factor for antibody binding. The amino acids substitutions and subsequent effects on structural stability and antibody binding can be performed by a homology based in-silico approach of the three-dimensional (3D) structure of E proteins. Hence, analyzing sequence data to annotate mutations at key residues and subsequent prediction of the effect of those mutations on protein structure stability is essential. Therefore, identifying novel amino acids mutations that are likely to contribute in the immune evasion is important.

In the present study, therefore, we extracted all of the available E protein sequences for Zika isolates obtained from 1968 to 2017 and constructed three-dimensional (3D) structures of E proteins from various Zika strains using homology modeling. We also investigated the patterns and conservation of E protein B-cell epitopes and assessed their structural stability upon mutation.

Methods

Data selection

Complete Zika polypeptide sequences for isolates identified between 1968 and 2017 were obtained from the National Center for Biotechnology Information (NCBI) Zika resource 28. A total of 409 complete polypeptide sequences were retrieved, and duplicate sequences were removed. Multiple sequence alignment was performed using MUSCLE in the Geneious tool, version 11.0, and the E protein region was extracted 29. Lastly, MUSCLE alignment was performed for E protein sequences and duplicate E sequences were subsequently removed.

Phylogenetic analysis

A phylogenetic tree for all unique Zika virus E protein sequences was constructed using the maximum-likelihood method with the PhyML tool, version 3.0 30, with 100 bootstrap replications. The tree applied an LG substitutional model to determine the divergence of E protein sequences. Lastly, the phylogenetic tree was edited using the Figtree tool, version 1.4.3.

Homology modeling

The SWISS model 31 server was used to generate 3D structures of the E proteins of Zika isolates identified in 1968, 2007, 2013, 2015, and 2016. Chain A of the E protein structure (PDB: 5GZN) was used as a template for homology modeling. The best homology model was selected based on global model quality estimate (GMQE) and Qmean statistics. Each homologous 3D structure was evaluated using Ramachandran plots prepared with PROCHECK 32. Hydrogen bonds were added using molprobity 33. Each model was subjected to energy minimization using the ModRefiner server described by Xu and Zhang 34.

Mapping of antigenic epitopes

E protein-specific antigenic epitopes of monoclonal antibodies (mAbs) isolated from Zika-virus infected humans and Zika immunized mice were retrieved from the Immune Epitope Database (IEDB) 35, which is a free resource funded by the National Institute of Allergy and Infectious Diseases devoted to disseminating antigenic epitope data. Linear and conformational B-cell epitopes with positive major histocompatibility complex ligands were selected. B-cell epitope regions mapped with B-cell receptor (BCR)-positive neutralizing antibodies were also selected. Epitopes that mapped with screening peptides and did not elicit an immune response were removed. A total of 7 human and 10 mouse (from mice immunized with E protein) B-cell epitopes were identified. The identified epitopes were annotated against aligned E sequences as well as the 3D structures of monomeric E proteins using the Chimera tool 36. Potential sites of N-glycosylation were predicted using NetNglycan 1.0 server 37. Potential N-glycosylation sites were defined by the sequence Asp/X/Ser/Thr, where X represents any amino acid except Pro. The default threshold of >0.5 was used as predictor of N-glycosylated residue.

Analysis of mutations on E protein stability

The effect of mutations on the stability of E protein was predicted using the mutation cutoff scanning matrix (mCSM) 38, site-directed mutator (SDM) 39, DUET 40, and I-Mutant 2.0 41 tools. The mCSM is a machine-learning algorithm based on a 3D physiochemical environment, and the data are summarized as a graphical signature. The SDM is a statistical potential energy function based on the propensity of amino acids in wild-type and mutant proteins to assume folded and unfolded conformations. DUET is an integrated computational approach that utilizes both SDM and mCSM to predict the effect of non-synonymous single-nucleotide polymorphisms on protein stability. Lastly, the I-Mutant webserver is a neural network-based tool for predicting mutation-associated free energy changes. The I-Mutant2.0 tool enables prediction of free energy changes under differing conditions of pH, temperature, neighboring residues, and solvent accessibility. For predicting protein stability, pH 7.0 and temperature at 25 C were applied.

Results

Strain frequencies

Antigenic variations among Zika strains were examined by first obtaining the complete sequences of Zika polypeptides from the NCBI Zika resource 19. A total of 409 Zika polypeptide sequences were retrieved. Identical polypeptide sequences were removed, resulting in a final total of 257 sequences. Sequences were aligned by MUSCLE using Geneious software, E protein sequences were extracted, and duplicate E protein sequences were removed, resulting in a total of 75 unique sequences ( Table 1). Of note, the majority of the 75 unique E protein sequences were represented strains isolated in 2015 and 2016. Sequences from isolates collected in 2017 did not harbor any unique mutations in comparison to sequences from isolates collected in previous years; thus, 2017 sequences were removed after duplicate E protein sequences were removed.

Table 1. List of unique E protein sequences and their frequency.

Number Accession Sequence Description Frequency N-Glycosylation
1 AMR68906 |Homo sapiens|Nigeria|09/09/1968 -
2 ACD75819 |Homo sapiens|Micronesia|01/06/2007 154 NDTG
3 AMR39834 |Homo sapiens|Cambodia|2010 2 154 NDTG
4 AMD61711 |Homo sapiens|Philippines|09/05/2012 154 NDTG
5 ANO46307 |Homo sapiens|French Polynesia|11/2013 154 NDTG
6 ANO46309 |Homo sapiens|French Polynesia|01/2014 154 NDTG
7 AMD61710 |Homo sapiens|Thailand|19/07/2014 154 NDTG
8 AMK49165 |Homo sapiens|Brazil|2015 154 NDTG
9 AMK49164 |Homo sapiens|Brazil|2015 154 NDTG
10 AOC50654 |Homo sapiens|Honduras|06/01/2015 154 NDTG
11 AMX81917 |Homo sapiens|Thailand|16/01/2015 154 NDTG
12 ASB32509 |Homo sapiens|Brazil|13/05/2015 4 154 NDTG
13 ALX35659 |Homo sapiens|Suriname|02/10/2015 154 NDTG
14 AMC13913 |Homo sapiens|Guatemala|01/11/2015 154 NDTG
15 AMD16557 |Homo sapiens|Brazil|30/11/2015 154 NDTG
16 ASU55392 |Homo sapiens|Colombia|12/2015 154 NDTG
17 ASU55393 |Homo sapiens|Colombia|12/2015 154 NDTG
18 ASU55394 |Homo sapiens|Colombia|12/2015 154 NDTG
19 ASU55403 |Homo sapiens|Colombia|12/2015 154 NDTG
20 ASU55399 |Homo sapiens|Colombia|12/2015 154 NDTG
21 ASU55411 |Homo sapiens|Colombia|12/2015 154 NDTG
22 ASU55407 |Homo sapiens|Colombia|12/2015 3 154 NDTG
23 ASU55396 |Homo sapiens|Colombia|12/2015 154 NDTG
24 ASU55398 |Homo sapiens|Colombia|12/2015 154 NDTG
25 ASU55409 |Homo sapiens|Colombia|12/2015 154 NDTG
26 AMQ48982 |Homo sapiens|Brazil|29/01/2016 154 NDTG
27 AMQ48986 |Homo sapiens|USA|02/02/2016 154 NDTG
28 AMK79469 |Homo sapiens|China|06/02/2016 154 NDTG
29 APC60216 |Homo sapiens|Mexico|03/03/2016 154 NDTG
30 AOY08538 |Homo sapiens|Brazil|21/03/2016 154 NDTG
31 AOX49265 |Homo sapiens|Italy|04/2016 2 154 NDTG
32 AQS26698 |Homo sapiens|South Korea|04/2016 -
33 AOY08534 |Homo sapiens|Brazil|05/04/2016 167 154 NDTG
34 ARB07987 |Homo sapiens|Dominican Republic|07/04/2016
Republic|07/04/20160Republic|2016/04/07		 154 NDTG
35 ARB07941 |Homo sapiens|Brazil|14/04/2016 -
36 ARB07968 |Homo sapiens|Brazil|15/04/2016 154 NDTG
37 ARB07988 |Homo sapiens|Dominican Republic|18/04/2016
Republic|2016/04/18		 154 NDTG
38 AQS26816 |Homo sapiens|Brazil|24/04/2016 154 NDTG
39 APG56499 |Homo sapiens|Taiwan|05/2016 154 NDTG
40 ATG29278 |Homo sapiens|Honduras|10/05/2016 154 NDTG
41 ARB07930 |Homo sapiens|Honduras|13/05/2016 154 NDTG
42 ATG29285 |Homo sapiens|Mexico|17/05/2016 154 NDTG
43 ART29823 |Homo sapiens|Russia|31/05/2016 154 NDTG
44 ARB07996 |Homo sapiens|DominicanRepublic|06/06/2016
r Republic04/07/4 Republic|2016/06/06		 154 NDTG
45 ARB07964 |Homo sapiens|Honduras|07/06/2016 154 NDTG
46 ARB07960 |Homo sapiens|Honduras|10/06/2016 154 NDTG
47 ARB07931 |Homo sapiens|Jamaica|13/06/2016 154 NDTG
48 AOY08535 |Homo sapiens|DominicanRepublic|14/06/2016
Republic|2016/06/14		 154 NDTG
49 APB03018 |Homo sapiens|USA|21/06/2016 154 NDTG
50 ARB07974 |Homo sapiens|Puerto Rico|26/06/2016 154 NDTG
51 ATG29297 |Homo sapiens|Mexico|05/07/2016 154 NDTG
52 ATG29280 |Homo sapiens|Mexico|06/07/2016 154 NDTG
53 ATG29301 |Homo sapiens|Mexico|07/07/2016 154 NDTG
54 ARB07936 |Homo sapiens|Jamaica|10/07/2016 154 NDTG
55 ATG29267 |Homo sapiens|Guatemala|21/07/2016 2 154 NDTG
56 APO39231 |Homo sapiens|USA|29/07/2016 154 NDTG
57 AQX32984 |Homo sapiens|Honduras|26/08/2016 154 NDTG
58 APH11519 |Homo sapiens|Singapore|27/08/2016 154 NDTG
59 APH11522 |Homo sapiens|Singapore|27/08/2016 154 NDTG
60 APH11526 |Homo sapiens|Singapore|27/08/2016 154 NDTG
61 APH11536 |Homo sapiens|Singapore|28/08/2016 154 NDTG
62 APH11556 |Homo sapiens|Singapore|28/08/2016 154 NDTG
63 APH11539 |Homo sapiens|Singapore|29/08/2016 154 NDTG
64 APH11534 |Homo sapiens|Singapore|30/08/2016 154 NDTG
65 APH11611 |Homo sapiens|Thailand|30/08/2016 154 NDTG
66 APH11493 |Homo sapiens|Singapore|04/09/2016 154 NDTG
67 APH11502 |Homo sapiens|Singapore|07/09/2016 4 154 NDTG
68 APH11511 |Homo sapiens|Singapore|13/09/2016 154 NDTG
69 APH11588 |Homo sapiens|Singapore|15/09/2016 154 NDTG
70 APO39241 |Homo sapiens|USA|03/10/2016 154 NDTG
71 AQX32988 |Homo sapiens|Venezuela|19/10/2016 154 NDTG
72 ARK18853 |Homo sapiens|China|01/11/2016 5 154 NDTG
73 APO08504 |Homo sapiens|China|03/11/2016 154 NDTG
74 BAX00477 |Homo sapiens|Japan|22/11/2016 154 NDTG
75 ASU55416 |Homo sapiens|Colombia|12/2016 2 154 NDTG
Open in a new tab

Phylogeny

A phylogenetic tree of unique E protein sequences was constructed using the maximum-likelihood function in PhyML software, with 100 bootstrap replications ( Figure 1). Zika strain accession numbers shown in the phylogenetic tree denote the year of isolation. Notably, E protein sequences from isolates collected in 1968, 2007, 2010, and 2012 clustered in one group, indicating that the associated strains are closely related ( Figure 1). However, sequences from strains isolated in 2013 and 2014 exhibited divergence from the sequences of strains isolated in previous years ( Figure 1).

Figure 1. Phylogenic tree of the unique E protein sequences between the years 1968–2017.

Figure 1.

Open in a new tab

Year 1968 colored (purple), 2007 (yellow), 2010 (cyan), 2012 (green), 2013(red), 2014 (brown), 2015(magenta), and 2016 (blue).

Antigenic epitopes

A number of recent reports describe the isolation of mAbs specific for Zika E protein 23– 28. These antibodies bind preferentially to epitopes located in DII and DIII of the E glycoprotein ( Table 2). A total of 7 neutralizing mAbs have been isolated from Zika-virus infected humans, and all of these mAbs bind to discontinuous epitopes of E protein. Of note, ZIKV-117 and ZIKV-19 mAbs recognize epitopes located in DII ( Table 2), whereas ZIKV-12 and ZIKV-15 mAbs recognize epitopes located in the FL region, and mAbs ZIKV-Z006, and ZIKV-116 as well as the ZKA 190 mAb recognize epitopes located in DIII. Significant overlap between antigenic epitopes specific for ZIKV-Z006 and ZIKV-116 was observed, as three residues in the epitope recognized by the ZIKV-116 mAb are shared with the epitope recognized by ZIKV-Z006 ( Table 2). In addition, the epitope region recognized by the ZKA 190 mAb overlapped with that of the mAb specific for ZIKV-Z006 in two amino acids residues.

Table 2. List of B cell epitopes of Zika E protein mapped with neutralizing antibodies from infected humans and vaccinated mice.

IEDB ID Epitope E Domain mAb References
Human Epitopes 605975 D67, Q89, K118 DII ZIKV-117 23
605976 T309, E393, K394 DIII ZIKV-116 23
605977 W101 FL ZIKV-15 23
605978 W101, F108 FL ZIKV-12 23
605979 W217, F218, D220, P222 DII ZIKV-19 23
628722 Y305, S306, L307, T309, A310, A311,
G334, T335, D336, K340, Q350, T351,
L352, V391, G392, E393, K394, K395		 DIII ZIKV-Z006 24
733913 Y305, A333, T335, E370, N371 DIII ZKA 190 25
Mouse Epitopes
Discontinuous 		540699 T76, Q77, W101, G102, G104, C105,
G106, L107, F108		 DII ZIKV-E-
2A10G6		 20
558355 K301, T315, K316, I317, P318, A319,
E320, T321, L322, T327, E329, N362,
V364, I365, T366, E367, S372, K373,
M374, M375, E377		 DIII (C-C’
loop)		 ZV-48 26
558356 L307, K340, P342, A343, Q344,
V347, D348, Q350, T351, L352, T353,
P354, L358, D384, Y386		 DIII (LR) ZV-54 26
558357 L307, K340, P342, A343, Q344,
V347, D348, Q350, T351, L352, T353,
P354, V355, L358, V391		 DIII (C-C’
loop)		 ZV-64 26
558358 T309, A310, A311, F312, T313, F314,
Q331, Y332, A333, G334, T335,
D336, G337, S368, E370, N371,
E393, K394, K395, I396, T397		 DIII (LR) ZV-67 26
Mouse Epitopes
Linear 		745460 D247, A248, H249, A250, K251,
R252, Q253, T254, V255, V256, V257,
L258, G259, S260, Q261, E262,
G263, A264, V265		 DII NA 27
745469 G383, D384, S385, Y386, I387, V388,
I389, G390, V391, G392, D393, K394		 DIII NA 27
745482 L300, K301, G302, V303, S304, Y305,
S306, L307, C308, T309, A310, A311,
F312, T313, F314, T315, K316, V317,
P318, A319, E320, T321		 DIII NA 27
753507 L352, T353, P354, V355, G356, R357,
L358, I359, T360, A361, N362, P363,
V364, I365, T366, E367		 DIII NA 27
745501 T427, A428, W429, D430, F431,
G432, S433, V434, G435, G436,
V437, F438, N439, S440, L441, G442,
K443		 DIII NA 27
Open in a new tab

A total of 10 B-cell epitopes of Zika E protein were found to elicit humoral antibody responses in vaccinated mice ( Table 2). Five of these epitopes were shown to be linear and elicited the production of neutralizing antibodies ( Table 2). An additional five discontinuous epitopes have been characterized based on antibodies obtained from vaccinated mice ( Table 2). The majority of those epitopes are bound to DIII domain of E.

To identify amino acid substitution mutations occurring in B-cell epitopes, we aligned the sequences of 75 unique E protein amino acids sequences among the 422 pre-epidemic and epidemic Zika strains identified. The sequence of Zika/Nigeria/9/9/1968 was used as a reference, and the E protein sequences were mapped against all of the mAbs from Zika infected humans or vaccinated mice. We then annotated the mutations in Zika E glycoprotein at predefined B-cell epitopes. Only nine Zika strains were found to carry mutations in the predefined B-cell epitopes recognized by mAbs from Zika-virus infected humans. Of note, two amino acids substitutions (R335T) and (D393E) appeared in 2007 ( Figure 2A). These amino acids substitutions were retained in all subsequent strains from 2007 to 2016. Interestingly, no unique mutations were observed in predefined B-cell epitopes for isolates collected between 2008 and 2014. However, in 2015, two additional substitutions of alanine residues for threonine residues appeared at amino acid positions 309 and 333 ( Figure 2A). These mutations were not retained in subsequently isolated Zika strains, with the sequences quickly reverting to those of previously isolated strains. The greatest number of amino acid substitution mutations occurred in 2016; the majority of the mutations identified in 2016 involved several deletions in specific regions of the predefined B-cell epitopes ( Figure 2A). Of note, the Dominican Republic/6/6/2016 strain exhibited significant deletions in B-cell epitopes recognized by ZIKV-Z006 mAb ( Figure 2A). Surprisingly, 3 B-cell epitopes were completely conserved in the pre-epidemic and epidemic strains and indeed have not changed for nearly 50 years ( Figure 2A). These epitopes are recognized by the mAbs ZIKV-117, ZIKV-15, and ZIKV-19. Thus, as these mAbs could exhibit cross-reactivity against a wide range of Zika strains, they have potential for use in the development of vaccines and immunotherapeutics targeting Zika ( Figure 2A).

Figure 2A. B-cell epitopes alignments mapped with human anti-E monoclonal antibodies.

Figure 2A.

Open in a new tab

A total of 9 Zika strains are variable at predefined B-cell epitopes during 1968–2017.

Conversely, none of 10 mouse B-cell epitopes were completely conserved among all Zika strains ( Figure 2B, Figure 2C). Of note, the number of Zika strains exhibiting variations in the amino acid sequence at predefined antigenic epitopes of the E protein was higher in mAbs characterized in vaccinated mice than in mAbs characterized in infected humans ( Figure 2B, Figure 2C). In addition, both the linear and discontinuous epitopes of vaccinated mice exhibited variations beginning in 2014 and continuing in subsequent years ( Figure 2B, Figure 2C). The majority of mAbs in vaccinated mice recognized the DIII of E protein, and these epitopes exhibited higher rates of sequence variation than did the mAbs recognizing DII ( Figure 2B, Figure 2C). Of note, the ZIKV-E-2A10G6 mAb binds to a highly conserved discontinuous epitope in which a single amino acid deletion was observed in Zika strain ATG29285| Homo sapiens|Mexico|17/05/2016. Remarkably, discontinuous epitopes bound the ZV-67 mAb exhibited the highest degree of variation in amino acid sequence among all the Zika B-cell epitopes examined ( Figure 2B). Sequence variations were also observed in all of the Zika E protein linear epitopes ( Figure 2C).

Figure 2B. Discontinuous B-cell epitopes alignments mapped with mice anti-E monoclonal antibodies.

Figure 2B.

Open in a new tab

A total of 18 Zika strains were variable at predefined B-cell epitopes during 1968–2017.

Figure 2C. Linear B-cell linear alignments mapped with mice anti-E antibodies.

Figure 2C.

Open in a new tab

A total of 20 Zika strains were variable at predefined B-cell epitopes during 1968–2017.

E protein homology modeling

The recently solved E protein structure of Zika enabled us to construct a homology model of various E protein sequences. Amino acid substitutions in B-cell epitopes were also annotated on the 3D structure of the E protein. The majority of mutations in the E protein were found to be located within DIII, whereas the B-cell epitopes in DII were highly conserved ( Figure 3). Zika strain Homo sapiens/French Polynesia/11/13 did not harbor any additional mutations in B-cell epitopes compared with Zika strain Homo sapiens/Micronesia/01/06/07 ( Supplementary Figure 1).

Figure 3. Comparison of B-cell epitopes of monomeric E between the years 1968, 2007, 2010, 2015, and 2016.

Figure 3.

Open in a new tab

Homology models of E were built from PDB: 5GZN chain A from strains of following E sequences: AMR68906| Homo sapiens |Nigeria|09/09/1968, ACD75819| Homo sapiens |Micronesia|01/06/2007, ANO46307| Homo sapiens/French Polynesia/11/2013, AMX81917/Homo sapiens/Thailand/16/01/2015, and AMQ48986 | Homo sapiens |USA|02/02/2016. Color blue color represents amino acids conservation at B-cell epitopes and color pink represents amino acids substitutions. Yellow label represent N-glycosylation potential of E.

It is known that N-glycosylation can mask antigenic epitopes. However, as the glycosylation site in the Zika E protein is located remotely from the predefined B-cell epitopes, glycosylation does not mask the B-cell antigenic epitopes ( Figure 3). This is consistent with reports of glycosylation in E protein of WNV and JEV 18. A recent report demonstrated that glycosylation at 154 is critical for Zika infection of both mammalian and mosquito hosts 17. Our analyses indicate that antigenic changes occur less frequently in Zika strains ( Figure 3) and suggest that highly effective neutralizing Zika vaccines and immunotherapies for treating infections with known Zika strains are possible. Consequently, monitoring antigenic changes in E proteins over time would be useful for evaluating the cross-neutralizing potential of Zika vaccines against newly mutated strains.

Mutational stability

Mutation stability was carried out to predict the effects of non-synonymous variants on the stability of E protein and antibody binding. Here, we analyzed the stability of monomeric E protein upon substitutional mutations. Amino acids substitutions can affect the strength, number of interaction, and protein folding and thus increase or decrease binding affinity. To investigate the effect of amino acids substitutions at antigenic epitopes on the stability of E protein and antibody binding of E, 4 prediction tools for mutational stability were selected.

We predicted the stability of B-cell epitope mutations using the 3D structure of Zika E proteins. In both the T309A and T335A substitutions, a polar threonine residue was substituted with a hydrophobic alanine residue. No change in hydrophobicity with the V391I mutation or change in charge with the D393E were observed. In the R335T mutation, a basic residue was substituted with an aromatic residue. Overall, these suggest that defined substitutions in the E glycoprotein are potentially destabilizing. However, these mutations had moderate destabilizing effect, as the ∆∆G values ranged between -0.3 and -0.7 kcal/mol ( Table 3).

Table 3. Mutational stability prediction of substituted amino acids at B-cell epitopes of E.

Mutations mCSM Effect SDM Effect DUET Effect I-Mutant2.0 Effect
T309A - 0.464 Kcal/mol Destabilizing 0.12 Kcal/mol Stabilizing -0.22 Kcal/mol Destabilizing -0.15 Kcal/mol Decreased
stability
T335A - 0.596 Kcal/mol Destabilizing 0.12 Kcal/mol Stabilizing -0.337 Kcal/mol Destabilizing 0.33 Kcal/mol Increased
stability
R335T - 0.304 Kcal/mol Destabilizing -0.38 Kcal/mol Destabilizing -0.173 Kcal/mol Destabilizing NA NA
V391I - 0.375 Kcal/mol Destabilizing 0.08 Stabilizing -0.022 Destabilizing -0.25 Kcal/mol Decreased
stability
D393E - 0.38 Kcal/mol Destabilizing 0.06 Kcal/mol Stabilizing -0.149 Kcal/mol Destabilizing NA NA
Open in a new tab

Discussion

Attempts to control the spread of Zika virus via mosquito control have met with limited success. Indeed, within the past 3 years, a Zika pandemic occurred. There is a significant gap in knowledge regarding immunogenic cross-reactivity between Zika strains, even six decades after the first human infection was reported. Bioinformatics approaches can play vital roles in identifying rapidly evolving amino acid residues and thereby facilitate precise mapping of key residues that drive antigenic escape in response to the generation of host neutralizing antibodies. In the present study, we evaluated conserved versus rapidly evolving antigenic regions in predefined B-cell epitopes of the Zika E protein in pre-epidemic and epidemic periods.

The finger-like DII of the Zika E protein contains a FL that is inserted into the endosomal membrane as a result of pH-dependent conformational changes 14. The FL is located within the beta-sheet structure in the terminal region of DII and contains a highly conserved hydrophobic peptide that triggers the structural changes required for fusion processes under conditions of low pH 15. Our analysis demonstrated that B-cell epitopes in DII of Zika E protein are highly conserved. mAbs ZIKV-117, ZIKV-15, and ZIKV-19 are bound to the highly conserved region of DII and are therefore attractive candidates in the design of Zika vaccines and immunotherapeutics.

The immunoglobulin-like DIII of the Zika E protein contains receptor-binding sites and plays an essential role in attachment and fusion of the virus to host cells 11, 12. Importantly, DIII reportedly induces the production of type-specific neutralizing antibodies 26, as mAbs isolated from patients infected with either Zika or dengue are highly specific. In the present study, we found that epitopes within E protein DIII vary greatly within Zika strains.

While dengue is considered as a single serotype, it is characterized by four distinct serotypes. The antibody-dependent enhancement (ADE) hypothesis holds that cross-reactive antibodies generated as a result of previous infections with heterologous flaviviruses can enhance the infectivity of other viruses 42, 43. Infection with the same serotype elicits a protective immune response, but re-infection with a different serotype can lead to serious disease 42, 43. Previous studies demonstrated that mAbs isolated from patients infected with dengue virus cross-react with Zika virus 44– 47.

Similarly, mAbs isolated from Zika patients directed against E protein DII cross-react with dengue 44, 48, indicating possible increased risk of ADE. Furthermore, another study demonstrated that dengue-virus derived mAbs also cross-react with Zika with high potency 20. Those mAbs are bound to quaternary epitopes, which include the site of interaction of E protein dimer with PrM during virus maturation 20. In contrast, most mAbs directed against DIII of Zika E protein do not cross-react with dengue 44.

In the present study, we compared mAbs of Zika E protein elicited in cases of Zika-virus infected humans versus mAbs induced by Zika vaccination in mice and identified several conserved epitope footprints. The conserved E protein epitopes could be useful in research aimed at developing vaccines that elicit the production of antibodies that provide protection against Zika strains but do not cross-react with dengue. For example, immunization with a peptide cocktail of antigenic DIII epitopes might provide broad protection against a variety of Zika strains yet demonstrate no cross-reactivity with dengue, thus eliminating the possibility of ADE associated with the anti-Zika antibodies.

Data availability

Zika protein sequences data can be found at the NCBI Zika resource.

Zika B-cell antigenic epitopes can be found at Immune Epitope Database (IEDB).

Acknowledgment

We would like to thank Arwa Alghamdi from College of Pharmacy at IAU who assisted in the research.

Funding Statement

The research was supported by Deanship of Scientific Research at Imam Abdulrahman Bin Faisal University [DSR 2017-376-IRMC].

The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.

[version 2; peer review: 2 approved]

Supplementary material

Supplementary Figure 1. Ramachandran plot analysis of 3D structure of monomeric E.

Supplementary Figure 1.

Open in a new tab

Homology model for sequences of |Nigeria|09/09/1968, ACD75819| Homo sapiens |Micronesia|01/06/2007, ANO46307| Homo sapiens/French Polynesia/11/2013, AMX81917/Homo sapiens/Thailand/16/01/2015, and AMQ48986 | Homo sapiens |USA|02/02/2016 were verified.

References

  • 1. Kuno G, Chang GJ: Full-length sequencing and genomic characterization of Bagaza, Kedougou, and Zika viruses. Arch Virol. 2007;152(4):687–696. 10.1007/s00705-006-0903-z [DOI] [PubMed] [Google Scholar]
  • 2. Lindenbach BD, Rice CM: Molecular biology of flaviviruses. Adv Virus Res. 2003;59:23–61. 10.1016/S0065-3527(03)59002-9 [DOI] [PubMed] [Google Scholar]
  • 3. Dick GW, Kitchen SF, Haddow AJ: Zika virus. I. Isolations and serological specificity. Trans R Soc Trop Med Hyg. 1952;46(5):509–520. 10.1016/0035-9203(52)90042-4 [DOI] [PubMed] [Google Scholar]
  • 4. Macnamara FN: Zika virus: a report on three cases of human infection during an epidemic of jaundice in Nigeria. Trans R Soc Trop Med Hyg. 1954;48(2):139–145. 10.1016/0035-9203(54)90006-1 [DOI] [PubMed] [Google Scholar]
  • 5. Duffy MR, Chen TH, Hancock WT, et al. : Zika virus outbreak on Yap Island, Federated States of Micronesia. N Engl J Med. 2009;360(24):2536–2543. 10.1056/NEJMoa0805715 [DOI] [PubMed] [Google Scholar]
  • 6. Cao-Lormeau VM, Roche C, Teissier A, et al. : Zika virus, French polynesia, South pacific, 2013. Emerg Infect Dis. 2014;20(6):1085–6. 10.3201/eid2006.140138 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 7. Zanluca C, Melo VC, Mosimann AL, et al. : First report of autochthonous transmission of Zika virus in Brazil. Mem Inst Oswaldo Cruz. 2015;110(4):569–572. 10.1590/0074-02760150192 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 8. Metsky HC, Matranga CB, Wohl S, et al. : Zika virus evolution and spread in the Americas. Nature. 2017;546(7658):411–415. 10.1038/nature22402 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 9. Apte-Sengupta S, Sirohi D, Kuhn RJ: Coupling of replication and assembly in flaviviruses. Curr Opin Virol. 2014;9:134–142. 10.1016/j.coviro.2014.09.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 10. Zhang Y, Corver J, Chipman PR, et al. : Structures of immature flavivirus particles. EMBO J. 2003;22(11):2604–2613. 10.1093/emboj/cdg270 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 11. Stadler K, Allison SL, Schalich J, et al. : Proteolytic activation of tick-borne encephalitis virus by furin. J Virol. 1997;71(11):8475–8481. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 12. Yu IM, Zhang W, Holdaway HA, et al. : Structure of the immature dengue virus at low pH primes proteolytic maturation. Science. 2008;319(5871):1834–1837. 10.1126/science.1153264 [DOI] [PubMed] [Google Scholar]
  • 13. Dai L, Song J, Lu X, et al. : Structures of the Zika Virus Envelope Protein and Its Complex with a Flavivirus Broadly Protective Antibody. Cell Host Microbe. 2016;19(5):696–704. 10.1016/j.chom.2016.04.013 [DOI] [PubMed] [Google Scholar]
  • 14. Modis Y, Ogata S, Clements D, et al. : Structure of the dengue virus envelope protein after membrane fusion. Nature. 2004;427(6972):313–9. 10.1038/nature02165 [DOI] [PubMed] [Google Scholar]
  • 15. Rey FA, Heinz FX, Mandl C, et al. : The envelope glycoprotein from tick-borne encephalitis virus at 2 A resolution. Nature. 1995;375(6529):291–8. 10.1038/375291a0 [DOI] [PubMed] [Google Scholar]
  • 16. Kostyuchenko VA, Lim EX, Zhang S, et al. : Structure of the thermally stable Zika virus. Nature. 2016;533(7603):425–8. 10.1038/nature17994 [DOI] [PubMed] [Google Scholar]
  • 17. Bressanelli S, Stiasny K, Allison SL, et al. : Structure of a flavivirus envelope glycoprotein in its low-pH-induced membrane fusion conformation. EMBO J. 2004;23(4):728–738. 10.1038/sj.emboj.7600064 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18. Vaughan AT, Roghanian A, Cragg MS: B cells--masters of the immunoverse. Int J Biochem Cell Biol. 2011;43(3):280–285. 10.1016/j.biocel.2010.12.005 [DOI] [PubMed] [Google Scholar]
  • 19. Heinz FX, Auer G, Stiasny K, et al. : The interactions of the flavivirus envelope proteins: implications for virus entry and release. Arch Virol Suppl. 1994;9:339–348. 10.1007/978-3-7091-9326-6_34 [DOI] [PubMed] [Google Scholar]
  • 20. Barba-Spaeth G, Dejnirattisai W, Rouvinski A, et al. : Structural basis of potent Zika-dengue virus antibody cross-neutralization. Nature. 2016;536(7614):48–53. 10.1038/nature18938 [DOI] [PubMed] [Google Scholar]
  • 21. Paul LM, Carlin ER, Jenkins MM, et al. : Dengue virus antibodies enhance Zika virus infection. Clin Transl Immunology. 2016;5(12):e117. 10.1038/cti.2016.72 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22. Xu X, Vaughan K, Weiskopf D, et al. : Identifying Candidate Targets of Immune Responses in Zika Virus Based on Homology to Epitopes in Other Flavivirus Species. PLoS Curr. 2016;8: pii: ecurrents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b. 10.1371/currents.outbreaks.9aa2e1fb61b0f632f58a098773008c4b [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 23. Sapparapu G, Fernandez E, Kose N, et al. : Neutralizing human antibodies prevent Zika virus replication and fetal disease in mice. Nature. 2016;540(7633):443–447. 10.1038/nature20564 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24. Robbiani DF, Bozzacco L, Keeffe JR, et al. : Recurrent Potent Human Neutralizing Antibodies to Zika Virus in Brazil and Mexico. Cell. 2017;169(4):597–609.e11. 10.1016/j.cell.2017.04.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 25. Wang J, Bardelli M, Espinosa DA, et al. : A Human Bi-specific Antibody against Zika Virus with High Therapeutic Potential. Cell. 2017;171(1):229–241.e15. 10.1016/j.cell.2017.09.002 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 26. Zhao H, Fernandez E, Dowd KA, et al. : Structural Basis of Zika Virus-Specific Antibody Protection. Cell. 2016;166(4):1016–1027. 10.1016/j.cell.2016.07.020 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27. Basu R, Zhai L, Contreras A, et al. : Immunization with phage virus-like particles displaying Zika virus potential B-cell epitopes neutralizes Zika virus infection of monkey kidney cells. Vaccine. 2018;36(10):1256–1264. 10.1016/j.vaccine.2018.01.056 [DOI] [PubMed] [Google Scholar]
  • 28. Hatcher EL, Zhdanov SA, Bao Y, et al. : Virus Variation Resource - improved response to emergent viral outbreaks. Nucleic Acids Res. 2017;45(D1):D482–D490. 10.1093/nar/gkw1065 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29. Kearse M, Moir R, Wilson A, et al. : Geneious Basic: an integrated and extendable desktop software platform for the organization and analysis of sequence data. Bioinformatics. 2012;28(12):1647–1649. 10.1093/bioinformatics/bts199 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 30. Guindon S, Dufayard JF, Lefort V, et al. : New algorithms and methods to estimate maximum-likelihood phylogenies: assessing the performance of PhyML 3.0. Syst Biol. 2010;59(3):307–321. 10.1093/sysbio/syq010 [DOI] [PubMed] [Google Scholar]
  • 31. Biasini M, Bienert S, Waterhouse A, et al. : SWISS-MODEL: modelling protein tertiary and quaternary structure using evolutionary information. Nucleic Acids Res. 2014;42(Web Server issue):W252–W258. 10.1093/nar/gku340 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 32. Laskowski RA, MacArthur MW, Moss DS, et al. : Procheck - A Program to Check the Stereochemical Quality of Protein Structures. J App Cryst. 1993;26:283–291. 10.1107/S0021889892009944 [DOI] [Google Scholar]
  • 33. Chen VB, Arendall WB, 3rd, Headd JJ, et al. : MolProbity: all-atom structure validation for macromolecular crystallography. Acta Crystallogr D Biol Crystallogr. 2010;66(Pt 1):12–21. 10.1107/S0907444909042073 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34. Xu D, Zhang Y: Improving the physical realism and structural accuracy of protein models by a two-step atomic-level energy minimization. Biophys J. 2011;101(10):2525–2534. 10.1016/j.bpj.2011.10.024 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35. Vita R, Overton JA, Greenbaum JA, et al. : The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43(Database issue):D405–D412. 10.1093/nar/gku938 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 36. Pettersen EF, Goddard TD, Huang CC, et al. : UCSF Chimera--a visualization system for exploratory research and analysis. J Comput Chem. 2004;25(13):1605–1612. 10.1002/jcc.20084 [DOI] [PubMed] [Google Scholar]
  • 37. Gupta R, Jung E, Brunak S: Prediction of N-Glycosylation Sites in Human Proteins.2004;46:203–206. [Google Scholar]
  • 38. Pires DE, Ascher DB, Blundell TL: mCSM: predicting the effects of mutations in proteins using graph-based signatures. Bioinformatics. 2014;30(3):335–342. 10.1093/bioinformatics/btt691 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 39. Worth CL, Preissner R, Blundell TL: SDM--a server for predicting effects of mutations on protein stability and malfunction. Nucleic Acids Res. 2011;39(Web Server issue):W215–W222. 10.1093/nar/gkr363 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 40. Pires DE, Ascher DB, Blundell TL: DUET: a server for predicting effects of mutations on protein stability using an integrated computational approach. Nucleic Acids Res. 2014;42(Web Server issue):W314–W319. 10.1093/nar/gku411 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41. Capriotti E, Fariselli P, Casadio R: I-Mutant2.0: predicting stability changes upon mutation from the protein sequence or structure. Nucleic Acids Res. 2005;33(Web Server issue):W306–W310. 10.1093/nar/gki375 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 42. Kliks SC, Nisalak A, Brandt WE, et al. : Antibody-dependent enhancement of dengue virus growth in human monocytes as a risk factor for dengue hemorrhagic fever. Am J Trop Med Hyg. 1989;40(4):444–451. 10.4269/ajtmh.1989.40.444 [DOI] [PubMed] [Google Scholar]
  • 43. Lobigs M, Diamond MS: Feasibility of cross-protective vaccination against flaviviruses of the Japanese encephalitis serocomplex. Expert Rev Vaccines. 2012;11(2):177–187. 10.1586/erv.11.180 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 44. Stettler K, Beltramello M, Espinosa DA, et al. : Specificity, cross-reactivity, and function of antibodies elicited by Zika virus infection. Science. 2016;353(6301):823–826. 10.1126/science.aaf8505 [DOI] [PubMed] [Google Scholar]
  • 45. Priyamvada L, Quicke KM, Hudson WH, et al. : Human antibody responses after dengue virus infection are highly cross-reactive to Zika virus. Proc Natl Acad Sci U S A. 2016;113(28):7852–7857. 10.1073/pnas.1607931113 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 46. Swanstrom JA, Plante JA, Plante KS, et al. : Dengue Virus Envelope Dimer Epitope Monoclonal Antibodies Isolated from Dengue Patients Are Protective against Zika Virus. mBio. 2016;7(4): pii: e01123-16. 10.1128/mBio.01123-16 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 47. Dejnirattisai W, Supasa P, Wongwiwat W, et al. : Dengue virus sero-cross-reactivity drives antibody-dependent enhancement of infection with zika virus. Nat Immunol. 2016;17(9):1102–8. 10.1038/ni.3515 [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 48. Kawiecki AB, Christofferson RC: Zika Virus-Induced Antibody Response Enhances Dengue Virus Serotype 2 Replication In Vitro. J Infect Dis. 2016;214(9):1357–1360. 10.1093/infdis/jiw377 [DOI] [PubMed] [Google Scholar]
F1000Res. 2019 Jul 1. doi: 10.5256/f1000research.21556.r50488

Reviewer response for version 2

Meirong Jia 1,2

Good for indexing.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

F1000Res. 2019 May 21. doi: 10.5256/f1000research.17985.r42684

Reviewer response for version 1

Sunil K Joshi 1,2

Authors described in-silico methods to delineate the data which are particularly important due to high mutation rates by RNA viruses which can generate mutations, that enable them to evade the host immune system. Authors emphasized the structural stability of E protein, which is a key factor for antibody binding. The bioinformatic analysis of B cell epitopes of Zika  is very important study in terms of developing effective vaccine and may be also in cross-protection against other similar viruses.

In the present study, the authors extracted all of the available E protein sequences for Zika isolates obtained from 1968 to 2017 and constructed three-dimensional (3D) structures of E proteins from various Zika strains using homology modelling. Further the authors investigated the patterns and conservation of E protein B-cell epitopes and assessed their structural stability upon mutation. The authors did meticulous data analysis and discussed very thoroughly.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard.

F1000Res. 2018 Nov 6. doi: 10.5256/f1000research.17985.r39301

Reviewer response for version 1

Meirong Jia 1,2

Summary:  Zika virus is still a big threat to human health, and E protein is its major structural determinant of immunity. The identification of B-cell epitopes of Zika E protein is crucial for the development of vaccines and immunotherapeutics. Here, the authors conducted systematic bioinformatics analyses of Zika strains isolated between 1968 and 2017, they’ve found conservative epitopes between Zika strains, which could be attractive targets for treating against diverse Zika strains. The research report is generally sound and the finding is scientifically valuable, which would provide guidance for later research in Zika vaccine development. Thus, I would recommend the indexing of this work in F1000Research.

The followings are some suggestions and comments that might help to make the report more suitable for indexing:

  1. In the ‘Introduction’ part, for the 2 nd paragraph, “After maturation, pr is released from the host cell” is that “PrM” being released instead?

  2. In ‘Table 2’, the first row, should “mAB” be “mAb”?

  3. In the ‘Abstract’, for the ‘Results’ part, “Our analyses indicate that epitopes recognized by human mAbsZIKV-117, ZIKV-15, and ZIKV-119 were highly conserved”. Should be “ZIKV-19”, please correct it. Also, since there is mutation as shown in ‘Fig 2B’ other than the strict conservation pattern in ‘Fig 2A’, please rewrite the claim that “ZIKV-E-2A10G6 mAb derived from immunized mice was highly conserved across Zika strains”.

  4. In the ‘Results’, for E protein homology modelling, the 2 nd paragraph, “Glycosylation does not mask the B-cell epitope epitopes” should be “antigenic epitopes?”

  5. In the ‘Method’ part, for ‘Mapping of antigenic epitopes’, “Potential N-glycosylation sites were defined by the sequence Asp/X/Ser/Thr, where X represents any amino acid except Pro. A threshold of >0.5 suggested an N-glycosylated residue.” Please further explain what values >0.5 would suggest an N-glycosylated residue.

  6. The authors described in the ‘Methods’ that “The I-Mutant2.0 tool enables prediction of free energy changes under differing conditions of pH, temperature, neighboring residues, and solvent accessibility.” For the data shown in ‘Table 3’, what conditions did authors apply to conduct the prediction?

  7. In the ‘Results’, the last paragraph, “Overall, these suggest that defined substitutions in the E glycoprotein are potentially destabilizing.” Could the authors further discuss what the consequence or effects of destabilization has on virus infection since authors said that the structural stability of E protein is a key factor for antibody binding.

  8. In the ‘Discussion’ part, the authors claimed that “The conserved E protein epitopes could be useful in research aimed at developing vaccines that elicit the production of antibodies that provide protection against Zika strains but do not cross-react with dengue.” Yet from the manuscript, it seems that no conserved epitopes in DIII has been identified. If so, authors might need to rewrite the last part of the discussion.

I confirm that I have read this submission and believe that I have an appropriate level of expertise to confirm that it is of an acceptable scientific standard, however I have significant reservations, as outlined above.

F1000Res. 2019 Jun 11.
Iman Almansour 1

We thank Dr.Jia for the careful reading of the manuscript and the constructive remarks.

Response to general comments:

1.Corrections has been made.

2.Corrections has been made.

3.Yes, thank you for pointing this out. Corrections were made.

4.Yes, we are sorry for the unintended mistake. Corrections were made.

5. Explanation has been made.

6.pH 7.0 and temperature at 25 C were applied. The details were added in the method section.

7.In the revised document, we further explained the effect of mutations on protein stability and protein binding (Results section, mutation stability, first paragraph).

8.In the discussion section, we have explained that immunization with a cocktail of antigenic DIII epitopes might provide broad protection against a variety of Zika strains.

Associated Data

    This section collects any data citations, data availability statements, or supplementary materials included in this article.

    Data Availability Statement

    Zika protein sequences data can be found at the NCBI Zika resource.

    Zika B-cell antigenic epitopes can be found at Immune Epitope Database (IEDB).

    Articles from F1000Research are provided here courtesy of F1000 Research Ltd

    RESOURCES